百奥泰与Avalon Pharma签署BAT3306(帕博利珠单抗)注射液授权商业化协议

Group 1 - The core point of the article is that Baiotai (688177.SH) has signed a licensing and commercialization agreement with Avalon Pharma for its BAT3306 (Pabrolizumab) injection in the Saudi and Middle East and North Africa markets, with potential total payments up to $7 million [1][2] - The agreement includes an upfront payment of $2 million, milestone payments not exceeding $5 million, and a two-digit percentage of net sales as revenue sharing [1] - BAT3306 (Pabrolizumab) is developed based on guidelines for biosimilars from the National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA) [1] Group 2 - The purpose of the agreement is to quickly transform the company's research and development achievements into economic benefits through commercial cooperation and licensing [2] - The collaboration with Avalon is expected to integrate advantages in research, production quality control, technology enhancement, clinical application, and commercial promotion, creating favorable conditions for the company's future development [2] - The successful implementation of the agreement is anticipated to have a positive impact on the company's future operating performance [2]